drugset / Trial / NCT06206174
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Phase 1/2
Recruiting
30 enrolled
Shenzhen TargetRx Co., Ltd.
Institute of Hematology & Blood Diseases Hospital, China · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, aute lymphoblastic leukemia and myelodysplastic syndromes.
Timeline
- Start
- 2024-03-06
- Primary completion
- 2025-02-28
- Completion
- 2029-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGRX-814 | Unknown | — | Oral |